KaloCyte was founded in 2016 by a distinguished team of Washington University in St. Louis researchers in physiology, bioengineering, and trauma care, with support from the BioGenerator Fundamentals program. KaloCyte has demonstrated proof of concept for ErythroMer, a dried, bio-inspired artificial red blood cell envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte has an exclusive license for the technology from Washington University, and is supported by nearly $6M in federal awards and investor funding.

For more information, visit KaloCyte or follow their updates on:

In 2019, BioGenerator Invested $3.2 Million in 16 Bioscience Companies in St. Louis

Which Startup Will Make it Big starting at Startup Connectionā€™s Tenth Anniversary event?